Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature

M. Chłopek, J. Lasota, LDR. Thompson, M. Szczepaniak, A. Kuźniacka, K. Hińcza, K. Kubicka, M. Kaczorowski, M. Newford, Y. Liu, A. Agaimy, W. Biernat, M. Durzyńska, I. Dziuba, A. Hartmann, S. Inaguma, E. Iżycka-Świeszewska, H. Kato, J. Kopczyński,...

. 2022 ; 35 (11) : 1609-1617. [pub] 20220817

Jazyk angličtina Země Spojené státy americké

Typ dokumentu přehledy, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032883

Sinonasal mucosal melanoma is a rare tumor arising within the nasal cavity, paranasal sinuses, or nasopharynx (sinonasal tract). This study evaluated 90 cases diagnosed in 29 males and 61 females with median age 68 years. Most tumors involved the nasal cavity and had an epithelioid morphology. Spectrum of research techniques used in this analysis includes targeted-DNA and -RNA next-generation sequencing, Sanger sequencing, fluorescence in situ hybridization and immunohistochemistry. Sinonasal melanomas were commonly driven by RAS (38/90, 42%), especially NRAS (n = 36) mutations and rarely (4/90, 4%) displayed BRAF pathogenic variants. BRAF/RAS mutants were more frequent among paranasal sinuses (10/14, 71%) than nasal (26/64, 41%) tumors. BRAF/RAS-wild type tumors occasionally harbored alterations of the key components and regulators of Ras-MAPK signaling pathway: NF1 mutations (1/17, 6%) or NF1 locus deletions (1/25, 4%), SPRED1 (3/25, 12%), PIK3CA (3/50, 6%), PTEN (4/50, 8%) and mTOR (1/50, 2%) mutations. These mutations often occurred in a mutually exclusive manner. In several tumors some of which were NRAS mutants, TP53 was deleted (6/48, 13%) and/or mutated (5/90, 6%). Variable nuclear accumulation of TP53, mirrored by elevated nuclear MDM2 expression was seen in >50% of cases. Furthermore, sinonasal melanomas (n = 7) including RAS/BRAF-wild type tumors (n = 5) harbored alterations of the key components and regulators of canonical WNT-pathway: APC (4/90, 4%), CTNNB1 (3/90, 3%) and AMER1 (1/90, 1%). Both, TERT promoter mutations (5/53, 9%) and fusions (2/40, 5%) were identified. The latter occurred in BRAF/RAS-wild type tumors. No oncogenic fusion gene transcripts previously reported in cutaneous melanomas were detected. Eight tumors including 7 BRAF/RAS-wild type cases expressed ADCK4::NUMBL cis-fusion transcripts. In summary, this study documented mutational activation of NRAS and other key components and regulators of Ras-MAPK signaling pathway such as SPRED1 in a majority of sinonasal melanomas.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032883
003      
CZ-PrNML
005      
20230131151131.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41379-022-01122-7 $2 doi
035    __
$a (PubMed)35978013
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chłopek, Małgorzata $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA $u Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland
245    10
$a Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature / $c M. Chłopek, J. Lasota, LDR. Thompson, M. Szczepaniak, A. Kuźniacka, K. Hińcza, K. Kubicka, M. Kaczorowski, M. Newford, Y. Liu, A. Agaimy, W. Biernat, M. Durzyńska, I. Dziuba, A. Hartmann, S. Inaguma, E. Iżycka-Świeszewska, H. Kato, J. Kopczyński, M. Michal, M. Michal, R. Pęksa, M. Prochorec-Sobieszek, A. Starzyńska, S. Takahashi, B. Wasąg, A. Kowalik, M. Miettinen
520    9_
$a Sinonasal mucosal melanoma is a rare tumor arising within the nasal cavity, paranasal sinuses, or nasopharynx (sinonasal tract). This study evaluated 90 cases diagnosed in 29 males and 61 females with median age 68 years. Most tumors involved the nasal cavity and had an epithelioid morphology. Spectrum of research techniques used in this analysis includes targeted-DNA and -RNA next-generation sequencing, Sanger sequencing, fluorescence in situ hybridization and immunohistochemistry. Sinonasal melanomas were commonly driven by RAS (38/90, 42%), especially NRAS (n = 36) mutations and rarely (4/90, 4%) displayed BRAF pathogenic variants. BRAF/RAS mutants were more frequent among paranasal sinuses (10/14, 71%) than nasal (26/64, 41%) tumors. BRAF/RAS-wild type tumors occasionally harbored alterations of the key components and regulators of Ras-MAPK signaling pathway: NF1 mutations (1/17, 6%) or NF1 locus deletions (1/25, 4%), SPRED1 (3/25, 12%), PIK3CA (3/50, 6%), PTEN (4/50, 8%) and mTOR (1/50, 2%) mutations. These mutations often occurred in a mutually exclusive manner. In several tumors some of which were NRAS mutants, TP53 was deleted (6/48, 13%) and/or mutated (5/90, 6%). Variable nuclear accumulation of TP53, mirrored by elevated nuclear MDM2 expression was seen in >50% of cases. Furthermore, sinonasal melanomas (n = 7) including RAS/BRAF-wild type tumors (n = 5) harbored alterations of the key components and regulators of canonical WNT-pathway: APC (4/90, 4%), CTNNB1 (3/90, 3%) and AMER1 (1/90, 1%). Both, TERT promoter mutations (5/53, 9%) and fusions (2/40, 5%) were identified. The latter occurred in BRAF/RAS-wild type tumors. No oncogenic fusion gene transcripts previously reported in cutaneous melanomas were detected. Eight tumors including 7 BRAF/RAS-wild type cases expressed ADCK4::NUMBL cis-fusion transcripts. In summary, this study documented mutational activation of NRAS and other key components and regulators of Ras-MAPK signaling pathway such as SPRED1 in a majority of sinonasal melanomas.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    12
$a melanom $x genetika $x patologie $7 D008545
650    12
$a nádory vedlejších dutin nosních $x genetika $x patologie $7 D010255
650    _2
$a mutace $7 D009154
650    _2
$a signální transdukce $7 D015398
650    12
$a paranazální dutiny $x patologie $7 D010256
650    _2
$a fosfatidylinositol-3-kinasy třídy I $x genetika $7 D058534
650    _2
$a TOR serin-threoninkinasy $x genetika $7 D058570
650    _2
$a RNA $7 D012313
650    _2
$a molekulární biologie $7 D008967
650    _2
$a mutační analýza DNA $7 D004252
655    _2
$a přehledy $7 D016454
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lasota, Jerzy $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA. jurek.p.lasota@gmail.com
700    1_
$a Thompson, Lester D R $u Head and Neck Pathology Consultations, Woodland Hills, CA, USA $1 https://orcid.org/0000000337141432
700    1_
$a Szczepaniak, Magdalena $u Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland
700    1_
$a Kuźniacka, Alina $u Department of Biology and Genetics, Medical University of Gdańsk, Gdańsk, Poland
700    1_
$a Hińcza, Kinga $u Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland
700    1_
$a Kubicka, Kamila $u Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland
700    1_
$a Kaczorowski, Maciej $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA $u Department of Clinical and Experimental Pathology, Wrocław Medical University, Wrocław, Poland
700    1_
$a Newford, Michael $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
700    1_
$a Liu, Yalan $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
700    1_
$a Agaimy, Abbas $u Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany $1 https://orcid.org/0000000204458161
700    1_
$a Biernat, Wojciech $u Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland $1 https://orcid.org/0000000184622189
700    1_
$a Durzyńska, Monika $u Department of Pathology, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland $1 https://orcid.org/0000000308588841
700    1_
$a Dziuba, Ireneusz $u Faculty of Medicine, University of Technology, Katowice, Poland
700    1_
$a Hartmann, Arndt $u Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany
700    1_
$a Inaguma, Shingo $u Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan
700    1_
$a Iżycka-Świeszewska, Ewa $u Department of Pathology and Neuropathology, Medical University of Gdańsk, Gdańsk, Poland $1 https://orcid.org/0000000175501326
700    1_
$a Kato, Hiroyuki $u Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan $1 https://orcid.org/0000000258886217
700    1_
$a Kopczyński, Janusz $u Department of Surgical Pathology, Holycross Cancer Center, Kielce, Poland
700    1_
$a Michal, Michal $u Sikl's Department of Pathology, University Hospital, Charles University in Prague, Medical Faculty in Plzeň, Plzeň, Czech Republic
700    1_
$a Michal, Michael $u Sikl's Department of Pathology, University Hospital, Charles University in Prague, Medical Faculty in Plzeň, Plzeň, Czech Republic $1 https://orcid.org/0000000344037027
700    1_
$a Pęksa, Rafał $u Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland $1 https://orcid.org/0000000249047059
700    1_
$a Prochorec-Sobieszek, Monika $u Department of Pathology, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Starzyńska, Anna $u Department of Oral Surgery, Medical University of Gdańsk, Gdańsk, Poland
700    1_
$a Takahashi, Satoru $u Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan $1 https://orcid.org/0000000281398158
700    1_
$a Wasąg, Bartosz $u Department of Biology and Genetics, Medical University of Gdańsk, Gdańsk, Poland $1 https://orcid.org/0000000236347562
700    1_
$a Kowalik, Artur $u Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland $u Division of Medical Biology, Institute of Biology Jan Kochanowski University, Kielce, Poland $1 https://orcid.org/000000023718999X
700    1_
$a Miettinen, Markku $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
773    0_
$w MED00003380 $t Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc $x 1530-0285 $g Roč. 35, č. 11 (2022), s. 1609-1617
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35978013 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151127 $b ABA008
999    __
$a ok $b bmc $g 1891562 $s 1184218
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 35 $c 11 $d 1609-1617 $e 20220817 $i 1530-0285 $m Modern pathology $n Mod Pathol $x MED00003380
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace